TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05786469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veltassa Oral Powder Product
Description: The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The recommended starting dose is 8.4 g of patiromer, once daily (equivalent to one packet of the active ingredient, once daily). The daily dose may be adjusted in intervals of one week or longer, based on the serum potassium level and the desired target range. The daily dose may be increased or decreased by 8.4 g as necessary to reach the desired target range, up to a maximum dose of 25.2 g daily. If serum potassium falls below the desired range, the dose should be reduced or discontinued.~Patients are expected to be included during an 18-month recruitment period. The last randomized patient will be maintained on active follow-up for 6 months. All other randomized patients will be maintained on active follow-up until the last randomized patient will have completed the planned 6-month follow-up period. Thus, the follow-up period will be expected to range from a minimum of 6 months for the last randomized patient to a maximum of 24 months for the first randomized patient
Study: NCT05017311

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: All patients will receive open-label escitalopram (10-20 mg/d) for the entire study duration (12 weeks).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole
Description: Depending on the initial randomization process, patients will either receive blinded brexpiprazole (0.5-2 mg/d) for the entire study duration (12 weeks) or for the last 4 weeks of the study if they received the placebo during the first 8 weeks of the study and were non-responders.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Brexpiprazole
Description: Depending on the initial randomization process, patients will either receive blinded brexpiprazole (0.5-2 mg/d) for the entire study duration (12 weeks) or for the last 4 weeks of the study if they received the placebo during the first 8 weeks of the study and were non-responders.
Study: NCT05154019

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Managing Minds at Work Online Training
Description: The intervention will be an online, interactive training course which will include evidence-based material, guidance, and practical exercises. The training will cover the following topics, presented as a series of independent, stand-alone modules:~Module one: Looking after your own mental health Module two: Designing and managing work to promote mental well-being Module three: Management Competencies that Prevent Work-related Stress Module four: Developing a Psychologically Safe Workplace Module five: Having conversations about mental health at work Each module will be designed to take between 20 and 30 minutes to complete. Participants will be permitted by their employer to complete the training within their work time. The training is self-led, so each participant can progress through each module at their own pace and at a time that suits them.
Study: NCT05816798

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photobiomodulation
Description: PBM is a therapeutic technique that uses light at different wavelengths (red or infrared), in a non-invasive way in which non-ionizing irradiation is used to produce a series of photophysical and photochemical effects when applied to biological tissues (humans and animals). Regarding the clinical results, numerous articles have already demonstrated the effect of PBM in improving pain and disability in patients with knee joint pain.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Physiotherapy Tretament
Description: standard treatment (physiotherapy-standard exercises: Cardiopulmonary physiotherapy and Physiotherapy with global muscle strengthening exercises). This program will be maintained for all study patients, for both groups, throughout the data collection period and includes activities 2X per week.)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard Physiotherapy Tretament
Description: standard treatment (physiotherapy-standard exercises: Cardiopulmonary physiotherapy and Physiotherapy with global muscle strengthening exercises). This program will be maintained for all study patients, for both groups, throughout the data collection period and includes activities 2X per week.)

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Photobiomodulation Placebo
Description: The same interventions described of Photobiomodulation Group bu device will be turned off
Study: NCT05702801

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stochastic Vibratory Stimulation (SVS)
Description: Investigators implement stochastic vibratory stimulation (SVS) to alter proprioceptive performance by increasing excitement of type Ia afferents in muscle spindles. Based on previous preliminary data, vibration frequencies around 40Hz may provide adequate noise for enhancing aging-related proprioceptive deficits. To make a subsensory noise investigators set it to 90% of the sensory threshold amplitude, which has been effectively used previously for influencing mechanoreceptor sensation in older adults. Stimulation will be imposed bilaterally on: 1) distal ankle (tibialis anterior, peroneus longus, soleus, gastrocnemius); and 2) proximal hip (quadriceps, gluteus medius, and paraspinals). Investigators use Gaussian noise to reduce the anticipative and preemptive adjustments of muscle spindles to the vibration. For SVS investigators use a magnetic actuator system and a Universal Controller (C-2HDLF Tactor/TDK), to provide programmable frequency ranges.
Study: NCT06002451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WEB-BASED PRECONCEPTİONAL CARE AND COUNSELİNG
Description: A web-based preconceptional care and consultancy training platform has been developed. In line with the literature, a comprehensive preconceptional care and counseling training content was prepared for women between the ages of 18-49. Web-based training consists of a total of 9 modules.The videos created for uploading to the website were shot in a professional studio environment with professional equipment.Each video was shot and recorded by dividing the training content according to its subsections, with an average of at least 6 minutes and a maximum of 16 minutes. Each of the module videos is based on giving the main messages in line with the purpose and objectives of the presentation.women were allowed to watch all the videos within 2 weeks. A dialog box is opened on the website where women can communicate with their midwives 24/7. During and after the training, preconceptional care and counseling training was given in this area for a total of 10 weeks.
Study: NCT06085326

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Smart Checklist
Description: The digitized Smart Checklist includes three new features that currently do not exist on a paper checklist: 1) decision support prompts based on patient-provider dyad characteristics, 2) real time display of patient pertinent airway information from the EHR, and 3) high-risk warning alerts based on predictive analytics with potential explanatory factors from the model.
Study: NCT06348797

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: α-PD-L1/4-1BB DLL3 CAR-T (BHP01)
Description: Preconditioning with fludarabine, cyclophosphamide, based chemotherapy regimen at sub-clinical doses; Bridge radiotherapy with 15 Gray (Gy)/5 fractions; α-PD-L1/4-1BB DLL3 CAR-T (BHP01): the first dose was 5x10\^5/kg.
Study: NCT05974488

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McMurray Enhanced Airway
Description: The MEA is non-sterile. It can be used in inpatient or outpatient surgery, in hospital or clinic settings, or in an emergency setting. The MEA has five parts: an optional 15 mm connector, flange (color-coded for size), elongated cushioned bite block, flexible cannula, and distal tip, and a channel to allow for passage of air and a suction catheter. The MEA is designed to open and maintain a patient's upper airway. Oxygen will be delivered through the breathing circuit with the following parameters: 40% oxygen at 6 liters/min flow throughout the procedure time. The MEA will be placed in the participant's oropharyngeal airway one time during an in-person visit.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasal Cannula
Description: Participants in this group will use the nasal cannula to deliver oxygen as per standard of care one time during the in-person visit.
Study: NCT05162625

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin Ophthalmic 0.5% Ophthalmic Solution
Description: Topical moxifloxacin 0,5% 01 drop every 3 hours

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciprofloxacin 400 MG/200 ML Intravenous Solution [CIPRO IV]
Description: Intravenous ciprofloxacin 400mg every 12 hours and cefazolin 1000mg every 6 hours
Study: NCT06489522

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: THRIVE
Description: THRIVE is a brief, parent child interaction therapy (PCIT) based telehealth intervention delivered over 6-sessions that has been tested in pediatric and community-based settings.
Study: NCT06339060

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Experimental: Arm 1 Organ preservation
Description: Arm 1 patients will undergo clinical response evaluations (CREs) after neoadjuvant therapy(A+B+C）, If cancer is detected, surgery will be performed. Patients with clinical complete response （cCR） are eligible for active surveillance where regular CREs are performed to detect regrowth of cancer.Postoperative adjuvant therapy will follow the NCCN guideline.~A: Camrelizumab 200mg IV on days 1 and 22 B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.~A+B+C=Neoadjuvant therapy

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Active Comparator: Arm 2 Surgery
Description: Arm 2 patients will undergo surgery after neoadjuvant therapy(B+C）.Postoperative adjuvant therapy will follow the NCCN guideline.~B: Carboplatin (AUC=2) IV and Paclitaxel-albumin (50mg/m²) IV on day 1,8,15,22,29.~C: Radiotherapy will start on day 1 of chemotherapy. A total of 41.4 Gy, 23 fractions of 1.8 Gy, 5 fractions a week.
Study: NCT06213818

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Oral; Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Oral; Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB160058
Description: Oral; soft gel capsule
Study: NCT06100900

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BCX10013
Description: Multiple dose levels may be tested in this study.
Study: NCT05038735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpelisib
Description: Alpelisib (tablets) administered at 300mg orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant (prefilled syringe) 500mg administered intramuscularly at Cycle 1 Day 1 and 15 and then at Day 1 of each subsequent cycle (each cycle is 28 days).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alpelisib-matching placebo
Description: Alpelisib-matching placebo (tablets) administered orally once daily on a continuous dosing schedule starting on Cycle 1 Day 1 in a 28 day cycle.
Study: NCT04726410

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cold Stored Platelets
Description: early infusion of urgent release CSP

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care
Description: standard care including room temperature platelets
Study: NCT05131425

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Facing Your Fears: ASD/ID
Description: This cognitive behavioral therapy, entitled Facing Your Fears for Adolescents with Autism and Intellectual Disability, is focused on somatic management, helpful cognitive mantras, emotion regulation, and graduated exposure adapted for the cognitive and linguistic needs of an Intellectual Disability population.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: The treatment as usual condition is being used in this study as a control condition. The investigators will track what medication and intervention services families are currently receiving.
Study: NCT04390009

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Entire-body PET-CT scans
Description: Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Entire-body PET-CT scans
Description: Entire-body PET-CT scans will be performed with state-of-the-art scanners with different manufacturers' models including Siemens Biograph Vision, United Imaging uEXPLORER and possibly other recently FDA-approved PET-CT scanners.

Intervention type: DRUG
Group type: OTHER
Intervention: Amyvid radiopharmaceutical
Description: Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants

Intervention type: DRUG
Group type: OTHER
Intervention: Amyvid radiopharmaceutical
Description: Amyvid (F18-florbetapir) will be evaluated for binding to white matter of the peripheral and central nervous system of participants
Study: NCT04848194

Intervention type: PROCEDURE
Group type: OTHER
Intervention: skin biopsy and blood sampling
Description: * 4 skin biopsies outside the face under local anesthesia: 2 in damaged zone, 2 in non-damage zone.~* A blood sample
Study: NCT05249426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 765063
Description: BI 765063 (anti-Signal Regulatory Protein Alpha (SIRPα) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezabenlimab
Description: Ezabenlimab (anti-Programmed cell death protein 1 (PD-1) Monoclonal Antibody (mAb))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: BI 836880 (anti-Vascular Endothelial Growth Factor (VEGF) / Angiopoetin 2 (Ang2))

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Investigator´s Choice Chemotherapy
Description: Allowable chemotherapies include: paclitaxel, docetaxel, capecitabine, 5-fluorouracil, methotrexate or combinations thereof
Study: NCT05564104

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cagrilintide
Description: Cagrilintide will be administered subcutaneously in the abdomen in the form of a solution for injection as well as intravenously in the form of solution for injection.
Study: NCT05628675

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Baby CHAT
Description: Baby CHAT is an approximately 90-minute group intervention to be delivered during pregnancy. The group is comprised of psychoeducational material about a baby's social development after birth and while the baby is growing in the womb. Attendees are encouraged to think about when an infant's social development begins and consider whether this occurs before or after birth. Participants are then shown a video clip of Reissland et al.'s (2016) study showing 4D ultrasound images of foetuses mouthing in response to sounds that are presented to them outside the womb. During Baby CHAT, parents are encouraged to reflect on this information in the context of their own baby's development, including their likes and dislikes, routine and personality. The final section of the group involves generating ideas for social activities that parents can try with their baby prior to birth, such as singing to, massaging or reading to their baby.
Study: NCT02919137

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visible light exposure
Description: Subjects will be exposed to visible colored light for 45 minutes. The visible light will be generated by red-green-blue light emitting diodes light cans.